Abstract
We report the use of a bispecific F(ab')2 antibody to target the ribosome-inactivating protein saporin to the surface antigen CD22 in the treatment of low-grade, end-stage, B-cell lymphoma. Four patients were treated. Toxic effects were minimal (grade I), with mild fever, weakness, and myalgia for 1-2 days after treatment. One patient showed an antibody response to mouse Fab' and saporin. All patients showed rapid and beneficial responses to treatment with improvements in most disease sites and in peripheral blood cytopenia. The responses were short-lived (less than 28 days) but further study of this targeting system is warranted.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Bispecific / administration & dosage
-
Antibodies, Bispecific / therapeutic use*
-
Antigens, CD / immunology
-
Antigens, Differentiation, B-Lymphocyte / immunology
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / immunology
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Cell Adhesion Molecules*
-
Drug Therapy, Combination
-
Epitopes / immunology
-
Female
-
Humans
-
Immunoglobulin Fab Fragments / immunology
-
Immunotoxins
-
Infusions, Intravenous
-
Lectins*
-
Lymphoma, B-Cell / therapy*
-
Male
-
Middle Aged
-
N-Glycosyl Hydrolases*
-
Plant Proteins / administration & dosage
-
Plant Proteins / immunology
-
Plant Proteins / therapeutic use*
-
Ribosome Inactivating Proteins, Type 1
-
Saporins
-
Sialic Acid Binding Ig-like Lectin 2
-
Treatment Outcome
Substances
-
Antibodies, Bispecific
-
Antigens, CD
-
Antigens, Differentiation, B-Lymphocyte
-
Antineoplastic Agents, Phytogenic
-
CD22 protein, human
-
Cell Adhesion Molecules
-
Epitopes
-
Immunoglobulin Fab Fragments
-
Immunotoxins
-
Lectins
-
Plant Proteins
-
Ribosome Inactivating Proteins, Type 1
-
Sialic Acid Binding Ig-like Lectin 2
-
N-Glycosyl Hydrolases
-
Saporins